納米魯單抗 （INN ：namilumab；開發代號：MT203 ），或譯那美蘆單抗 ，是一種人單株抗體 （IgG1 κ 類），靶向粒細胞-巨噬細胞集落刺激因子 （簡稱GM-CSF或CSF2），目前正在研究用於類風濕性關節炎 和銀屑病關節炎 。[1] [2] [3] 銀屑病 [4] [5] [6]
納米魯單抗由武田製藥 國際公司開發並由Micromet Inc生產。[3] [7]
參考資料 [ 編輯 ]
^ World Health Organization . International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104 (PDF) . WHO Drug Information. 2010, 24 (4). ^ Huizinga T, Batalov A, Stoilov R, Lloyd E, Wagner T, Saurigny D, Souberbielle B, Esfandiari E. Namilumab, an Anti-Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Monoclonal Antibody: Results of the First Study in Patients with Mild-to-Moderate Rheumatoid Arthritis (RA): Abstract Number: 969 . Arthritis & Rheumatology. October 2015, 67 . ^ 3.0 3.1 Namilumab . Adis Insight. Springer Nature Switzerland AG. [2017-03-24 ] . ^ Clinical trial number NCT02129777
^ A 24-week Randomized, Open-Label, Parallel-Group, Active-Controlled, Exploratory, Proof-of-Mechanism Imaging Study Investigating the Efficacy of 150 mg of Namilumab Administered Subcutaneously vs Adalimumab in Patients With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate . Adis Insight. Springer Nature Switzerland AG. [2017-03-24 ] . ^ Clinical trial number NCT02379091
^ Namilumab . Takeda clinical trials summary.
趨化因子受體 集落刺激因子 (CSF)
細胞因子受體
IFNAR (α/β, I)
激動劑： Albinterferon Interferon alpha (interferon alfa, IFN-α) Interferon alfa (IFNA1 , IFNA2 , IFNA4 , IFNA5 , IFNA6 , IFNA7 , IFNA8 , IFNA10 , IFNA13 , IFNA14 , IFNA16 , IFNA17 , IFNA21 )Interferon alfa 2a Interferon alfa 2b Interferon alfa n1 Interferon alfacon-1 Interferon alpha-n3 Interferon beta (IFN-β) (IFNB1 , IFNB3 )Interferon beta 1a Interferon beta 1b Interferon kappa (IFN-ε/κ/τ/ζ, IFNK) Interferon omega (IFN-ω, IFNW1) Peginterferon alfa-2a Peginterferon alfa-2b IFNGR (γ, II) IFNLR (λ, III)
白介素受體 TGFβ型受體 TNF受體超家族 其它
